The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.
Read the full articleYou might also wanna read
AstraZeneca’s Wainua fails main goal in late-stage heart disease trial
Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems
BBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’
AstraZeneca and Ionis announced on Thursday that their late-stage CARDIO-TTRansform trial for eplontersen (Wainua) failed to meet its main g
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up
A Phase 3 trial failure has erased a year of gains for Ionis Pharmaceuticals in just days, and the ripple effects are rattling rivals across
Astrazeneca shares fall 9% after Wainua heart drug fails Phase 3 trial
Svensk-britiske Astrazeneca er havnet i modvind på børsen torsdag oven på et sæt skuffende resultater fra et fase 3-studie med hjertemidlet
finans.dk·7d ago
AstraZeneca Stock Tumbles 6% Following Late-Stage Heart Disease Drug Trial Failure
AstraZeneca stock fell 9% after its Wainua heart drug trial missed its primary goal, raising questions about management credibility.
AstraZeneca sees stock market value slump by more than £20bn after drug setback
The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.
Comments
Sign in to join the conversation.
No comments yet. Be the first.